NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients (Q44766920)

6 December 2017

NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients (English)

1 reference

6 December 2017

0 references

1

1 reference

6 December 2017

Dominique Costagliola

12

1 reference

6 December 2017

Matthias Cavassini

3

0 references

Giuseppe Pantaleo

14

object named as

Giuseppe Pantaleo

1 reference

6 December 2017

2

Virginie Rozot

1 reference

6 December 2017

Felicitas Bellutti Enders

4

1 reference

6 December 2017

Selena Vigano

5

1 reference

6 December 2017

Gonzalo Tapia

6

1 reference

6 December 2017

Erika Castro

7

1 reference

6 December 2017

Séverine Burnet

8

1 reference

6 December 2017

Joep Lange

9

1 reference

6 December 2017

Christiane Moog

10

1 reference

6 December 2017

Daniel Garin

11

1 reference

6 December 2017

Brigitte Autran

13

1 reference

6 December 2017

Pierre-Alexandre Bart

15

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 October 2012

1 reference

European Journal of Immunology

6 December 2017

1 reference

6 December 2017

42

1 reference

6 December 2017

11

1 reference

6 December 2017

3038-3048

1 reference

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

6 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

AIDS. Boosting immunity to HIV--can the virus help?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Therapeutic vaccines for chronic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

T-cell quality in memory and protection: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Clinical studies of experimental vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Phenotype and function of protective T cell immune responses in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Diminished Proliferation of Human Immunodeficiency Virus-Specific CD4+T Cells Is Associated with Diminished Interleukin-2 (IL-2) Production and Is Recovered by Exogenous IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

SPICE: exploration and analysis of post-cytometric complex multivariate datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

7 January 2021

Interruption of Antiretroviral Therapy Initiated during Primary HIV-1 Infection: Impact of a Therapeutic Vaccination Strategy Combined with Interleukin (IL)-2 Compared with IL-2 Alone in the ANRS 095 Randomized Study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

7 January 2021

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

7 January 2021

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

7 January 2021

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242696

7 January 2021

HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population

1 reference

2 April 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/EJI.201242696

Identifiers

DOI

10.1002/EJI.201242696

1 reference

release_xtdirkv4qjdsjlrisa2jfgh3ry

6 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xtdirkv4qjdsjlrisa2jfgh3ry

24 November 2022

mapped directly with Wikidata item

1 reference